AbCellera is a Vancouver-based biotechnology company specializing in antibody discovery and development using advanced AI-powered platforms. Its unique technology rapidly screens natural immune responses to identify promising therapeutic antibodies. AbCellera differentiates itself through speed and scalability, enabling pharmaceutical partners to advance drug candidates faster. The company played a pivotal role in COVID-19 antibody therapies and maintains a strong Canadian footprint with cutting-edge labs and collaborative R&D partnerships. AbCellera continues to expand in Vancouver, recruiting scientists, engineers, and business professionals committed to transforming the way antibody drugs are discovered and brought to market.